Authors: SCHWARTSMANN G HOROWITZ M DILEONE L SANDER E CAMPOS O FERREIRA AF SCHUNEMANN H VIEGAS MAV CANCELA AI MANS DRA

Citation: G. Schwartsmann et al., PHASE-I TRIAL OF THE BOMBESIN RECEPTOR ANTAGONIST RC-3095 IN PATIENTSWITH REFRACTORY SOLID TUMORS, Annals of oncology, 9, 1998, pp. 651-651

Authors: SCHWARTSMANN G DILEONE L CALDAS APF CAMPOS O CANCELA AI VIEGAS MAV MANS DRA

Citation: G. Schwartsmann et al., PHASE-I AND PHARMACOKINETIC STUDY OF LOW-DOSE, 3-TIMES DAILY ORAL ETOPOSIDE IN PATIENTS WITH REFRACTORY SOLID TUMORS, Annals of oncology, 9, 1998, pp. 660-660

Authors: SCHWARTSMANN G MANS DRA DILEONE L CALDAS APF CAMPOS O SANDER E BORTOLINI M VIEGAS MAV CANCELA AI

Citation: G. Schwartsmann et al., PHASE-I AND PHARMACOKINETIC STUDY OF ORAL ETOPOSIDE GIVEN 3-TIMES DAILY ORALLY TO PATIENTS WITH REFRACTORY SOLID TUMORS, Annals of oncology, 9, 1998, pp. 252-252

Authors: SCHWARTSMANN G HOROWITZ M DILEONE L SANDER E CAMPOS O FERREIRA AF SCHUNEMANN H VIEGAS MAV CANCELA AI MANS DRA

Citation: G. Schwartsmann et al., PHASE-I TRIAL OF THE BOMBESIN RECEPTOR ANTAGONIST RC-3095 IN PATIENTSWITH REFRACTORY SOLID TUMORS, Annals of oncology, 9, 1998, pp. 420-420